Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1

Andrea CALCAGNO; Lucio BOGLIONE; De Rosa FG; Perri G Di; S Bonora

doi:10.1093/cid/cit087

Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1

Andrea CALCAGNO
, Lucio BOGLIONE
, De Rosa FG
, Perri G Di
, S Bonora

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Altro contributo

Lingua originale	Inglese
DOI	https://doi.org/10.1093/cid/cit087
Stato di pubblicazione	Pubblicato - 2013

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

Antiviral Agents
therapeutic use
Genotype
Hepacivirus
genetics
Hepatitis C
drug therapy
Humans
Oligopeptides
therapeuti/c use
Proline
analogs /&/ derivatives

Accesso al documento

10.1093/cid/cit087

http://hdl.handle.net/11579/114006

Altri file e collegamenti

handle

Cita questo

@misc{a4ebe6a944ee40a0b3e9e8b8dc87cf59,

title = "Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1",

keywords = "Antiviral Agents, therapeutic use, Genotype, Hepacivirus, genetics, Hepatitis C, drug therapy, Humans, Oligopeptides, therapeuti/c use, Proline, analogs /\&/ derivatives, Antiviral Agents, therapeutic use, Genotype, Hepacivirus, genetics, Hepatitis C, drug therapy, Humans, Oligopeptides, therapeuti/c use, Proline, analogs /\&/ derivatives",

author = "Andrea CALCAGNO and Lucio BOGLIONE and FG, \{De Rosa\} and Di, \{Perri G\} and S Bonora",

year = "2013",

doi = "10.1093/cid/cit087",

language = "English",

type = "Other",

}

TY - GEN

T1 - Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1

AU - CALCAGNO, Andrea

AU - BOGLIONE, Lucio

AU - FG, De Rosa

AU - Di, Perri G

AU - Bonora, S

PY - 2013

Y1 - 2013

KW - Antiviral Agents

KW - therapeutic use

KW - Genotype

KW - Hepacivirus

KW - genetics

KW - Hepatitis C

KW - drug therapy

KW - Humans

KW - Oligopeptides

KW - therapeuti/c use

KW - Proline

KW - analogs /&/ derivatives